Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Mar 30, 2025

LS174T

RRID:CVCL_1384
Type: Cell Line

Proper Citation

(RRID:CVCL_1384)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1384

Proper Citation: (RRID:CVCL_1384)

Sex: Female

Defining Citation: PMID:327080, PMID:833871, PMID:1262041, PMID:1999484, PMID:3335022, PMID:3349466, PMID:3518877, PMID:3664476, PMID:6401685, PMID:6652615, PMID:6935474, PMID:7370982, PMID:7459858, PMID:7972006, PMID:8422623, PMID:8464898, PMID:8895552, PMID:9000147, PMID:9290701, PMID:9294210, PMID:10674020, PMID:10737795, PMID:11226274, PMID:11414198, PMID:11416159, PMID:11526487, PMID:12068308, PMID:12606785, PMID:15900046, PMID:16418264, PMID:16854228, PMID:18258742, PMID:19132987, PMID:20164919, PMID:20215515, PMID:20570890, PMID:20606684, PMID:23272949, PMID:24042735, PMID:24755471, PMID:24840470, PMID:25485619, PMID:25877200, PMID:25926053, PMID:25944804, PMID:26537799, PMID:26589293, PMID:28196595, PMID:28683746, PMID:29101300

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Category: Cancer cell line

Name: LS174T

Synonyms: Ls174T, LS174t, Ls-174-T, LS-174-T, LS 174 T, LS-174T, Ls-174T, LS 174T, LS-174, LS174, Laboratory of Surgery 174T

Cross References: BTO:BTO_0001553, CLO:CLO_0007393, CLO:CLO_0007403, EFO:EFO_0002227, MCCL:MCC:0000504, CLDB:cl3261, AddexBio:C0009013/379, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ATCC:CL-188, ATCC:CCL-188, BCRC:60053, BioSample:SAMN03470826, BioSample:SAMN03471296, cancercelllines:CVCL_1384, CCRID:1101HUM-PUMC000248, CCRID:3101HUMTCHu32, CCRID:4201HUM-CCTCC00135, CCTCC:GDC0135, Cell_Model_Passport:SIDM01200, ChEMBL-Cells:CHEMBL3307536, ChEMBL-Targets:CHEMBL614097, CLS:300392, ColonAtlas:LS174T, Cosmic:711255, Cosmic:719679, Cosmic:724843, Cosmic:738927, Cosmic:873703, Cosmic:875424, Cosmic:876717, Cosmic:887219, Cosmic:889533, Cosmic:907793, Cosmic:934563, Cosmic:948131, Cosmic:948856, Cosmic:985998, Cosmic:995405, Cosmic:1043822, Cosmic:1057755, Cosmic:1066210, Cosmic:1122328, Cosmic:1132565, Cosmic:1132692, Cosmic:1187310, Cosmic:1184087, Cosmic:1184334, Cosmic:1312305, Cosmic:1479573, Cosmic:1486134, Cosmic:1524341, Cosmic:1676738, Cosmic:1708419, Cosmic:1805263, Cosmic:2301546, Cosmic:2301997, Cosmic:2646768, Cosmic:2651866, Cosmic:2668256, Cosmic:2760087, Cosmic:2787546, DSMZ:ACC-759, DSMZCellDive:ACC-759, ECACC:87060401, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM513911, GEO:GSM514297, GEO:GSM741264, GEO:GSM784021, GEO:GSM827345, GEO:GSM1346883, GEO:GSM1374632, GEO:GSM1374633, GEO:GSM1448164, GEO:GSM2550009, IARC_TP53:21478, IARC_TP53:21708, IGRhCellID:LS174T, KCB:KCB 200829YJ, KCLB:10188, LINCS_LDP:LCL-1182, Lonza:1127, MetaboLights:MTBLS227, NCBI_Iran:C568, PharmacoDB:LS174T_862_2019, PRIDE:PXD005354, PRIDE:PXD005355, Progenetix:CVCL_1384, PubChem_Cell_line:CVCL_1384, RCB:RCB1961, TKG:TKG 0406, TOKU-E:2235, Ubigene:YC-C088, Wikidata:Q54903053

ID: CVCL_1384

Record Creation Time: 20250131T201244+0000

Record Last Update: 20250131T202823+0000

Ratings and Alerts

No rating or validation information has been found for LS174T.

Warning: Discontinued: RCB; RCB1961
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line. Warning: Discontinued: ATCC; CCL-188
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Protein expression by reverse-phase protein arrays.,

Omics: O-glycan profiling., Omics: N-glycan profiling., Omics: miRNA expression profiling., Omics: Deep proteome analysis., Omics: Deep exome analysis., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: AstraZeneca Colorectal cell line (AZCL) panel., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 399 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Nessler I, et al. (2024) Improving Intracellular Delivery of an Antibody-Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses In Vivo. Molecular cancer therapeutics, 23(3), 343.

Aoki K, et al. (2024) NELF and PAF1C complexes are core transcriptional machineries controlling colon cancer stemness. Oncogene, 43(8), 566.

Boutin L, et al. (2024) Camelid-derived Tcell engagers harnessing human ?? T cells as promising antitumor immunotherapeutic agents. European journal of immunology, 54(8), e2350773.

Li HM, et al. (2024) PHGDH knockdown increases sensitivity to SR1, an aryl hydrocarbon receptor antagonist, in colorectal cancer by activating the autophagy pathway. The FEBS journal.

Ikari N, et al. (2024) Mieap forms membrane-less organelles involved in cardiolipin metabolism. iScience, 27(2), 108916.

Lee CJ, et al. (2024) The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. Nature communications, 15(1), 10422.

Wang Y, et al. (2024) Ginsenosides retard atherogenesis via remodelling host-microbiome metabolic homeostasis. British journal of pharmacology.

Baro L, et al. (2024) Tumor invasiveness is regulated by the concerted function of APC, formins, and Arp2/3 complex. iScience, 27(5), 109687.

McDonald RC, et al. (2024) Oxygen Sensor-Guided Fine Needle Biopsy Studies of Human Cancer Xenografts in Mice. bioRxiv : the preprint server for biology.

Zhu S, et al. (2023) A cancer cell membrane coated, doxorubicin and microRNA co-encapsulated nanoplatform for colorectal cancer theranostics. Molecular therapy oncolytics,

28, 182.

Murce E, et al. (2023) Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics. Pharmaceuticals (Basel, Switzerland), 16(6).

Feng J, et al. (2023) Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer. Oncogene, 42(20), 1620.

Plüss L, et al. (2023) Generation and in vivo characterization of a novel high-affinity human antibody targeting carcinoembryonic antigen. mAbs, 15(1), 2217964.

Sivasubramanian M, et al. (2023) Illuminating and Radiosensitizing Tumors with 2DG-Bound Gold-Based Nanomedicine for Targeted CT Imaging and Therapy. Nanomaterials (Basel, Switzerland), 13(11).

Yao Q, et al. (2023) The Milk Active Ingredient, 2'-Fucosyllactose, Inhibits Inflammation and Promotes MUC2 Secretion in LS174T Goblet Cells In Vitro. Foods (Basel, Switzerland), 12(1).

He S, et al. (2023) CD166-specific CAR-T cells potently target colorectal cancer cells. Translational oncology, 27, 101575.

Ramakrishnan AB, et al. (2023) SOX9 and TCF transcription factors associate to mediate Wnt/?-catenin target gene activation in colorectal cancer. The Journal of biological chemistry, 299(1), 102735.

Yuan Y, et al. (2023) LncRNA LINC01232 Enhances Proliferation, Angiogenesis, Migration and Invasion of Colon Adenocarcinoma Cells by Downregulating miR-181a-5p. Journal of microbiology and biotechnology, 33(3), 398.

Fan F, et al. (2023) Combining MEK and SRC inhibitors for treatment of colorectal cancer demonstrate increased efficacy in vitro but not in vivo. PloS one, 18(3), e0281063.

Zhang Y, et al. (2023) Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors. Research (Washington, D.C.), 6, 0077.